Oncology Institute, Inc. (TOI)
2025-06-30 | 2024-06-30 | |||
|---|---|---|---|---|
| Total operating revenue | 119,802 | 98,578 | ||
| Direct costs | - | 85,323 | ||
| Selling, general and administrative expense | 26,907 | 27,872 | ||
| Depreciation and amortization | 1,805 | 1,518 | ||
| Direct costs-Health Care Patient Service | 51,150 | - | ||
| Direct costs-Dispensary Revenue | 51,086 | - | ||
| Direct costs-Clinical Research Trials And Other Revenue | 65 | - | ||
| Total operating expenses | 131,013 | 114,942 | ||
| Loss from operations | -11,211 | -16,364 | ||
| Other, net | -19 | -117 | ||
| Interest expense, net | 1,870 | 2,118 | ||
| Change in fair value of derivative warrant liabilities | 53 | -552 | ||
| Change in fair value of conversion option derivative liabilities | -3,987 | 2,568 | ||
| Total other non-operating loss (income) | -5,929 | 885 | ||
| Loss before provision for income taxes | -17,140 | -15,479 | ||
| Income tax benefit (expense) | -131 | - | ||
| Net loss | -17,009 | -15,479 | ||
| Basic (in dollars per share) | -0.15 | -0.17 | ||
| Basic (in shares) | 93,203,665 | 74,748,365 | ||
| Diluted (in dollars per share) | -0.15 | -0.17 | ||
| Diluted (in shares) | 93,203,665 | 74,748,365 | ||